Skip to main content
. 2020 Jun 4;8(1):e000500. doi: 10.1136/jitc-2019-000500

Figure 2.

Figure 2

Kaplan-Meier estimates of OS, PFS, TDD in HRQoL and PF by ETS status for atezolizumab-treated patients from OAK and POPLAR. ETS, early tumor shrinkage; HRQoL, health-related quality-of-life; OS, overall survival; PF, physical function; PFS, progression-free survival; TDD, time to deterioration.